Bone News and Research

RSS

Novel imaging technique reveals new visual resolution of NK cell action

Scientists reveal in more detail than ever before how white blood cells kill diseased tissue using deadly granules, in research published today in PLoS Biology.

16 Sep 2011

Memphis operation successfully separates twins joined at the spine

Joshua and Jacob Spates, all of seven months old spent their initial months outside the womb as conjoined twins. Now they are recovering in the pediatric intensive care unit of a Memphis hospital after a successful 13-hour surgery to separate them.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Natural killer white blood cells caught on film

Scientists reveal in more detail than ever before how white blood cells kill diseased tissue using deadly granules, in research published today in PLoS Biology.

14 Sep 2011

Cohera's TissuGlu Surgical Adhesive receives CE Mark approval

Cohera Medical, Inc., a rapidly growing medical device company, announced today that it has received CE Mark approval for its lead product, TissuGlu® Surgical Adhesive. CE Mark approval allows TissuGlu to be sold in the European Union.

14 Sep 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Thyroid-stimulating hormone can promote bone growth

Researchers at Mount Sinai School of Medicine have found that thyroid-stimulating hormone (TSH), a hormone produced in the anterior pituitary gland that regulates endocrine function in the thyroid gland, can promote bone growth independent of its usual thyroid functions.

14 Sep 2011

Update to federally mandated system significantly expands number of diagnostic codes used by health care providers

Today, hospitals and doctors use a system of about 18,000 codes to describe medical services in bills they send to insurers. Apparently, that doesn't allow for quite enough nuance. A new federally mandated version will expand the number to around 140,000 - adding codes that describe precisely what bone was broken, or which artery is receiving a stent.

14 Sep 2011

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

13 Sep 2011

Cancer prevention tips for men at every stage of life

Men who maintain a healthy body throughout life are often better able to fight off diseases like cancer. That's why experts at The University of Texas MD Anderson Cancer Center have created a guide with cancer prevention tips to help men at every stage of life.

13 Sep 2011

EpiCept announces FDA's feedback on Ceplene clinical development for AML

EpiCept Corporation today announced that at a recent meeting with the U.S. Food and Drug Administration (FDA) the Company was provided more definitive guidance regarding the clinical development of Ceplene, the Company's lead product administered with interleukin-2 (IL-2) for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission.

12 Sep 2011

FDA advisory panel suggests warning for bisphosphonates but does not specify wording

Two independent advisory panels to the Food and Drug Administration (FDA) on Friday recommended increasing the cautionary language on the product labels of bone-building drugs taken by more than five million women in the United States. They did not however mention the exact words of the safety warnings and did not recommend limiting use of the drugs to a proposed five years. About 11 percent of women 55 and older take the drugs to prevent bone fractures.

12 Sep 2011

IBN scientists harness ultrasmall peptides to repair spinal disc damage

New ultrasmall peptides that can be used as building blocks for a wide range of regenerative applications such as spinal disc replacement and cartilage repair have been developed by scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute. These peptides spontaneously assemble in water to form hydrogels, which resemble collagen, a major component of connective tissues found in cartilage, ligaments, tendons, bone and skin.

12 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

12 Sep 2011

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

9 Sep 2011

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free - at least in mice - of dangerous side effects plaguing some current diabetes medications.

9 Sep 2011

Bone News and Research

Novel imaging technique reveals new visual resolution of NK cell action

Memphis operation successfully separates twins joined at the spine

KAI enters KAI-4169 development and commercialization agreement with Ono

Natural killer white blood cells caught on film

Cohera's TissuGlu Surgical Adhesive receives CE Mark approval

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Thyroid-stimulating hormone can promote bone growth

Update to federally mandated system significantly expands number of diagnostic codes used by health care providers

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Cancer prevention tips for men at every stage of life

EpiCept announces FDA's feedback on Ceplene clinical development for AML

FDA advisory panel suggests warning for bisphosphonates but does not specify wording

IBN scientists harness ultrasmall peptides to repair spinal disc damage

LC-MRM could provide better understanding of multiple myeloma drug resistance

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Au. sediba demonstrates unique combination of features, never before seen in early human ancestors

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Smith & Nephew launches DYONICS PLATINUM Series Shaver Blades for arthroscopy procedures

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News